摘要
目的观察银杏酮酯滴丸联合阿加曲班注射液治疗急性脑梗死的临床效果。方法采用前瞻性病例对照研究,选取山西中医药大学附属医院2020年4月至2021年4月收治的急性脑梗死患者120例为观察对象,采用随机数字表法分为常规组、研究组各60例。常规组在常规治疗基础上采用阿加曲班静脉注射治疗,研究组在常规治疗基础上采用银杏酮酯滴丸联合阿加曲班注射液治疗,连续治疗2周后评价临床疗效。结果研究组总有效率为95.0%(57/60),高于常规组的80.0%(48/60),差异有统计学意义(χ^(2)=6.17,P=0.012)。治疗后,研究组巴氏指数[(65.3±7.3)分]高于常规组[(59.8±7.5)分],改良Rankin量表(mRS)评分[(1.2±0.4)分]、美国国立卫生研究院卒中量表(NIHSS)评分[(4.6±0.7)分]均低于常规组[(2.4±0.6)分、(7.6±1.1)分](t=-4.07、12.89、17.82,均P<0.001);研究组白细胞介素6、超敏C反应蛋白、肿瘤坏死因子ɑ均低于常规组(t=10.10、18.25、14.15,均P<0.001);研究组一氧化氮高于常规组,而内皮素1、血栓素A2均低于常规组(t=-7.65、10.77、21.90,均P<0.001)。两组不良反应发生率差异无统计学意义(P>0.05)。结论银杏酮酯滴丸联合阿加曲班注射液治疗急性脑梗死疗效显著,能减轻患者神经功能缺损程度,促使其脑功能恢复,提高患者生活质量,调整血清炎症因子,值得临床应用。
Objective To investigate the clinical efficacy of ginkgo ketone ester dropping pills combined with agatroban injection in the treatment of acute cerebral infarction.Methods This prospective case-control study was conducted on 120 patients with acute cerebral infarction who were treated at The Hospital of Shanxi University of Chinese Medicine between April 2020 and April 2022.These patients were randomly divided into a control group and a study group using the random number table method,with 60 patients in each group.The control group received intravenous injections of agatroban based on conventional treatment,while the study group received treatment with ginkgo ketone ester dropping pills combined with agatroban injection based on conventional treatment.The treatment duration was 2 weeks.Clinical efficacy was evaluated after continuous treatment for 2 weeks.Results The overall response rate in the study group was 95.0%(57/60),which was significantly higher than 80.0%(48/60)in the control group(χ^(2)=6.17,P=0.012).After treatment,the Barthel index in the study group was(65.3±7.3)points,which was significantly higher than(59.8±7.5)points in the control group(t=-4.07,P<0.001).The modified Rankin Scale score and the National Institutes of Health Stroke Scale score in the study group were(1.2±0.4)points and(4.6±0.7)points,which were significantly lower than(2.4±0.6)points and(7.6±1.1)points,respectively,in the control group(t=12.89,17.82,both P<0.001).Interleukin-6,hypersensitive C-reactive protein,and tumor necrosis factor-αlevels in the study group were significantly lower than those in the control group(t=10.10,18.25,14.15,all P<0.001).The nitric oxide levels in the study group were significantly higher than those in the control group,while endothelin 1 and thromboxane A2 levels in the study group were significantly lower than those in the control group(t=-7.65,10.77,21.90,all P<0.001).There was no significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion The combina
作者
郭海霞
Guo Haixia(Department of Encephalopathy,The Hospital of Shanxi University of Chinese Medicine,Taiyuan 030000,Shanxi Province,China)
出处
《中国基层医药》
CAS
2024年第1期14-18,共5页
Chinese Journal of Primary Medicine and Pharmacy
关键词
脑梗死
药物疗法
联合
白细胞介素6
C反应蛋白质
肿瘤坏死因子Α
生活质量
银杏酮酯滴丸
阿加曲班
Brain infarction
Drug therapy,combination
Interleukin-6
C-reactive protein
Tumor necrosis factor-alpha
Quality of life Ginkgo ketone ester dropping pills
Agatroban
